LeMaitre Vascular (NASDAQ:LMAT) Stock Gets Price Target Reduction from Citizens Jmp

LeMaitre Vascular (NASDAQ:LMAT) had its price objective lowered by equities research analysts at Citizens Jmp from $127.00 to $110.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “market outperform” rating on the medical instruments supplier’s stock. Citizens Jmp‘s target price would suggest a potential upside of 25.11% from the company’s current price.

A number of other research firms also recently commented on LMAT. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd. Seaport Research Partners set a $110.00 target price on shares of LeMaitre Vascular in a research report on Thursday. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a research report on Thursday. Finally, Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus target price of $105.60.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock opened at $87.92 on Thursday. LeMaitre Vascular has a 12 month low of $78.22 and a 12 month high of $118.01. The stock has a market cap of $2.01 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The business has a fifty day simple moving average of $81.38 and a 200-day simple moving average of $94.16.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.04). The business had revenue of $67.97 million for the quarter, compared to analysts’ expectations of $67.39 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The company’s revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm earned $0.75 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

Institutional Investors Weigh In On LeMaitre Vascular

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in LeMaitre Vascular in the second quarter valued at about $314,075,000. Boston Trust Walden Corp bought a new stake in LeMaitre Vascular during the third quarter worth about $28,546,000. Ranger Investment Management L.P. acquired a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $21,045,000. Rice Hall James & Associates LLC acquired a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $18,223,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $16,549,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.